Full Breakdown
Multi-State Lawsuit Challenges Federal Medicaid Ban on Gender-Affirming Care for Transgender Youth
9/3/2026, 2:16:39 AM
Core Event
Attorney General Letitia James of New York, together with 20 other state attorneys general and the governor of Pennsylvania, filed a lawsuit in 2026 against the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS). The suit contests a final rule issued in early August 2026 that bars Medicaid and Children’s Health Insurance Program (CHIP) reimbursement for gender-affirming treatments—puberty-delaying medications, hormone therapies, and related surgeries—when used to treat gender dysphoria in patients under 18 (or 19 for CHIP).
Background & Context
States have historically received federal reimbursement for health services provided to transgender adolescents. The new CMS rule creates a nationwide prohibition, allowing reimbursement only when the same treatments are used for other medical conditions such as endocrine disorders or precocious puberty. More than 90 % of the public comments submitted to CMS opposed the rule, including comments from Attorney General James and leading medical organizations.
Data & Statistics
- Transgender youth in New York: 3.13 % of state adolescents identify as transgender, an estimated 37,000 individuals (Williams Institute).
- Public opposition: Over 90 % of CMS comment submissions rejected the rule.
- Mental-health impact: The Trevor Project reported that suicide attempts among transgender youth rose up to 72 % in the first year after state-level restrictions on gender-affirming care were enacted.
Official Statements & Responses
Attorney General James asserted that the federal rule exceeds CMS’s statutory authority and infringes on states’ rights to determine medically necessary care. The coalition of plaintiffs argues that Congress never granted CMS the power to unilaterally deny reimbursement for evidence-based health services that states have lawfully chosen to cover. They also contend that the rule’s justification relied on an HHS report that violated federal transparency requirements and ignored substantial medical evidence submitted during rulemaking.
Why It Matters / Impact
The plaintiffs maintain that the rule creates illegal barriers for low-income transgender patients who depend on Medicaid or CHIP to afford gender-affirming treatment. They warn that states continuing to cover such care would face significant new costs and administrative burdens previously offset by federal reimbursement. The lawsuit seeks a judicial declaration that the final rule is unlawful and an injunction to halt its enforcement in the participating states.
Verbatim Quote
- “The federal government does not have the authority to dictate what medically necessary care New York provides to its residents,” — Attorney General James, new york attorney
What’s Next
The complaint asks the federal court to strike down the CMS rule and to prevent its enforcement in the states that joined the lawsuit. The case will proceed through the district courts, with the plaintiffs indicating they will pursue further appellate relief if necessary.
